In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $459.81 in the prior trading day, Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) closed at $458.49, down -0.29%. In other words, the price has decreased by -$0.29 from its previous closing price. On the day, 0.8 million shares were traded. VRTX stock price reached its highest trading level at $462.31 during the session, while it also had its lowest trading level at $456.83.
Ratios:
Our goal is to gain a better understanding of VRTX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.29 and its Current Ratio is at 2.65. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
On May 06, 2025, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $503.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 21 ’25 when LR 2019 Benefit Trust bought 170 shares for $447.18 per share.
SR 2019 Benefit Trust bought 170 shares of VRTX for $76,021 on May 21 ’25. On May 15 ’25, another insider, ALTSHULER DAVID, who serves as the EVP, Chief Scientific Officer of the company, sold 52 shares for $424.69 each. As a result, the insider received 22,084 and left with 23,281 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRTX now has a Market Capitalization of 117738848256 and an Enterprise Value of 109774004224. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.66 while its Price-to-Book (P/B) ratio in mrq is 7.14. Its current Enterprise Value per Revenue stands at 9.89 whereas that against EBITDA is 23.945.
Stock Price History:
The Beta on a monthly basis for VRTX is 0.44, which has changed by -0.07279545 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, VRTX has reached a high of $519.88, while it has fallen to a 52-week low of $377.85. The 50-Day Moving Average of the stock is 2.10%, while the 200-Day Moving Average is calculated to be -1.09%.
Shares Statistics:
The stock has traded on average 1.54M shares per day over the past 3-months and 1029370 shares per day over the last 10 days, according to various share statistics. A total of 256.97M shares are outstanding, with a floating share count of 256.08M. Insiders hold about 0.28% of the company’s shares, while institutions hold 94.81% stake in the company. Shares short for VRTX as of 1749772800 were 4034849 with a Short Ratio of 2.84, compared to 1747267200 on 4824964. Therefore, it implies a Short% of Shares Outstanding of 4034849 and a Short% of Float of 1.77.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
At present, 24.0 analysts are actively evaluating the performance of Vertex Pharmaceuticals, Inc (VRTX) in the stock market.The consensus estimate for the next quarter is $4.6, with high estimates of $4.9 and low estimates of $4.0.
Analysts are recommending an EPS of between $18.79 and $17.19 for the fiscal current year, implying an average EPS of $18.0. EPS for the following year is $20.65, with 26.0 analysts recommending between $26.71 and $16.56.
Revenue Estimates
20 analysts predict $2.9B in revenue for the current quarter. It ranges from a high estimate of $3.01B to a low estimate of $2.8B. As of the current estimate, Vertex Pharmaceuticals, Inc’s year-ago sales were $2.65BFor the next quarter, 20 analysts are estimating revenue of $3.03B. There is a high estimate of $3.08B for the next quarter, whereas the lowest estimate is $2.98B.
A total of 24 analysts have provided revenue estimates for VRTX’s current fiscal year. The highest revenue estimate was $11.96B, while the lowest revenue estimate was $11.85B, resulting in an average revenue estimate of $11.91B. In the same quarter a year ago, actual revenue was $11.02BBased on 29 analysts’ estimates, the company’s revenue will be $13.17B in the next fiscal year. The high estimate is $14.36B and the low estimate is $11.94B.
